Table S1 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer

Key Points

• Precision treatment refines traditional therapy for HR+/HER2- breast cancer, enhancing patient outcomes significantly.
• Retrospective clinical cohorts reveal substantial improvements in treatment customization for HR+/HER2- cases.
• Analysis of patient data from clinical cohorts provides insights into optimizing treatment pathways in breast cancer management.
• Highlights potential shifts needed in therapeutic approaches for HR+/HER2- breast cancer based on cohort findings.